Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Diabetes
100%
Early Adolescence
100%
De-novo mutations
100%
SUR1
100%
Hyperinsulinism
100%
Overt Diabetes
100%
ABCC8 Gene
66%
Sulfonylurea Therapy
66%
Intravenous Glucose
66%
Genotype
33%
Cell Surface
33%
Co-transfection
33%
Cell Function
33%
Mutant Protein
33%
Channel Activity
33%
New Onset
33%
Glucose Level
33%
Cell Apoptosis
33%
Non-diabetic
33%
Insulin Secretion
33%
Sweet
33%
Glucose Tolerance Test
33%
Mutation Analysis
33%
Metabolic Demand
33%
Congenital Hyperinsulinism
33%
ABCC8
33%
Continuous Glucose Monitoring
33%
KCNJ11 Gene
33%
Convulsive Disorders
33%
Hypoglycemic Episodes
33%
Poor School Performance
33%
Glibenclamide
33%
Neonatal Hypoglycemia
33%
Large-for-gestational-age
33%
ATP-sensitive K+ (KATP) Channel
33%
Antibody-negative
33%
Medicine and Dentistry
Diabetes
100%
Infancy
100%
Sulfonylurea Receptor 1
100%
Hyperinsulinism
100%
Adolescence
100%
Glucose
60%
Sulfonylurea
40%
Body Mass Index
20%
In Vitro
20%
Programmed Cell Death
20%
Insulin Release
20%
Research Design
20%
Cell Surface
20%
Cell Function
20%
Adenosine Triphosphate
20%
Antidiabetic Agent
20%
Potassium Channel
20%
Glucose Tolerance
20%
Congenital Hyperinsulinism
20%
Induced Mutation
20%
Neonatal Hypoglycemia
20%
Large for Gestational Age
20%
Glibenclamide
20%
Kir6.2
20%
Oral
20%
Neuroscience
Sulfonylurea Receptor 1
100%
Glucose
100%
Sulfonylurea
50%
In Vitro
25%
Cell Function
25%
Adenosine Triphosphate
25%
Research Design
25%
Potassium Channel
25%
Body Mass Index
25%
Hypoglycemia
25%
Congenital Hyperinsulinism
25%
Insulin
25%
Kir6.2
25%
Glibenclamide
25%
Programmed Cell Death
25%
Pharmacology, Toxicology and Pharmaceutical Science
Sulfonylurea Receptor 1
100%
Hyperinsulinism
100%
Glucose
100%
Sulfonylurea
50%
Adenosine Triphosphate
25%
Hypoglycemia
25%
Antidiabetic Agent
25%
Potassium Channel
25%
Persistent Hyperinsulinemic Hypoglycemia of Infancy
25%
Insulin
25%
Large for Gestational Age
25%
Glibenclamide
25%